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Abstract
OBJECTIVE: To explore the regulatory effects of es-
tablished Chinese herbal formulas on inflammatory
mediators released during asthma attacks, and to
elucidate the molecular mechanism of Traditional
Chinese Medicine in the treatment of asthma.
METHODS: Seventy-five asthmatic children were
randomly divided into a Chinese medication group
(45 cases) and a Western medication control group
(30 cases). Patients in the Chinese medication
group were treated with a series of established Chi-
nese herbal formulas, whereas the Western medica-
tion control group received a leukotriene receptor
antagonist and a bronchial relaxant. Real-time PCR
was used to determine the mRNA expression levels
of interleukin (IL)-4, cysteinyl leukotriene receptor 1
(CysLTR1), and interferon (IFN)-γ in peripheral
blood mononuclear cells before and after treat-
ment. Enzyme-linked immunosorbent assay was
used to measure the peripheral blood levels of IL-4,
leukotriene (LTE)-4, and INF-γ before and after treat-
ment.
RESULTS: After treatment, the mRNA expression
levels of IL-4 and CysLTR1 were down-regulated (P<
0.01) and the mRNA expression levels of IFN-γ were
up-regulated (P<0.05) in the Chinese medication
and Western medication groups; no significant dif-
ference was found between the two groups. In the
Chinese medication group, IL-4 blood level was de-
creased and it was significantly different from
that in the Western medication group (P<0.05);
there was also a significant increase in IFN-γ
blood levels after treatment with Chinese medica-
tion (P<0.05). There were no significant differenc-
es in LTE-4 blood levels between the two groups
before and after treatment (P>0.05).
CONCLUSION: Chinese medication has a regulato-
ry effect on leukotriene receptor gene expression
and the imbalance of Th1/Th2 immune cells dur-
ing asthma attacks in pediatric patients.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
Bronchial asthma involves chronic airway inflamma-
tion characterized by participation of eosinophilic gran-
ulocytes, T cells, mast cells, and cytokines. Recently,
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the morbidity and mortality of bronchial asthma has
been increasing.1 Studies have shown that the patho-
genesis of airway inflammation in bronchial asthma pa-
tients may have a close relationship with cell number
and activation status, as well as an imbalanced ratio of
Th1and Th2 cell function.2 In addition, cysteinyl leu-
kotrienes also plays an important role in the develop-
ment of bronchial asthma. Traditional Chinese Medi-
cine (TCM) treatments for asthma have achieved good
results. Professor Yumin Shi, a senior TCM pediatric
expert, treated pediatric asthma based on the different
stages and symptoms of this disease. As a result, the use
of empirical prescriptions for asthma effectively con-
trolled asthma attacks and improved lung function.3
However, the mechanism of the empirical prescriptions
is fully unclear. The aim of this molecular biology
study was to investigate the regulatory effect of
stage-treatment with established Chinese herbal formu-
las on the inflammatory mediators and cytokines re-
leased during asthma attacks, so that to provide theoret-
ical basis for clinical practice.
MATERIALS ANDMETHODS
Diagnosis and differentiation standard
The diagnosis of bronchial asthma in Western Medi-
cine is consistent with the "Diagnosis and Prevention
Guideline for Bronchial asthma in children (2008
Edition)" by the Pediatric Respiratory Study Group
of the Chinese Medical Association.4 The "Criteria of
diagnostic efficacy of TCM Syndrome" by the State
Administration of Traditional Chinese Medicine5 is
referenced as a TCM diagnosis and differentiation
standard.
Inclusion and exclusion criteria
Patients were included if they (a) were satisfying the
above-mentioned diagnostic criteria with pediatric asth-
ma and cough variation asthma, (b) aged 3-12 years,
and (c) were with pattern of phlegm-heat obstruction
and cold fluid-retention in lungs at the acute stage, or
with pattern of lung-spleen deficiency and kidney Qi
deficiency at the remission stage of asthma based on
TCM Syndrome differentiation diagnosis. Patients
were excluded if they had congenital respiratory system
diseases, tumors, immunodeficiency diseases, or cardio-
vascular diseases.
Subjects
The research had been approved by the ethical commit-
tee of Children's Hospital of Fudan University (Shang-
hai, China). Meanwhile informed consent was ob-
tained from all participants. All of the 75 pediatric pa-
tients enrolled in the present clinical study were out-pa-
tients treated for asthma in the authors' hospital from
May 2008 to November 2012. Based on a random dig-
its table, all the patients were randomly divided into a
Chinese medication group (45 cases) and a Western
medication control group (30 cases). There were 21
boys and 9 girls with a mean age of（5.0±2.5）years
and a mean disease course of（14.9 ± 1.4）months in
the Western medication group. Within this group,
there were 24 asthma cases, 6 cases of cough variation
asthma, and 17 cases associated with allergic rhinitis.
Twenty-seven cases were with pattern of phlegm-heat
obstruction in lungs at the acute stage and 3 with pat-
tern of kidney Qi deficiency. In the Chinese medica-
tion group, there were 30 male and 15 female with a
mean age of（5.3±2.8）years and a mean disease course
of（14.2 ± 2.8）months. In this group, there were 30
asthma cases, 15 cases of cough variation asthma, and
12 cases associated with allergic rhinitis. Forty cases
were with pattern of phlegm-heat obstruction in lungs
at the acute stage, 5 with pattern of cold fluid-reten-
tion in the lungs at the acute stage, 41 with pattern of
lung-spleen deficiency, and 4 with pattern of deficiency
of kidney Qi at the remission stage of asthma. Compar-
ison of the general characteristics between the two
groups showed no statistically significant differences
(P>0.05), which indicated that the data of these two
groups were comparable.
Treatment
In the Chinese medication group, patients at the acute
stage of asthma were given Shegan (Rhizoma Belamcan-
dae) mixture (hospital preparation, commissioned pro-
cessing by Shanghai Liantang Pharmaceutical Produc-
tion, Shanghai, China, batch number 20090411). The
ingredients for each 10 mL of this preparation includ-
ed 0.6 g of Mahuang (Herba Ephedra Sinica), 1.5 g of
Shegan (Rhizoma Belamcandae), 1.5 g of Huangqin
(Radix Scutellariae Baicalensis), 1 g of Kuxingren (Se-
men Armeniacae Amarum), 5 g of Hancai (Herba Ror-
ippae Islandicae), and 1.5 g of Jiangcan (Bombyx Ba-
tryticatus). Patients took 10 mL of this mixture 3
times a day, for 7 days. At the remission stage, chil-
dren were treated with a Huangqi (Radix Astragali
Mongolici) Bushen mixture-based formulation with
modification according to their symptoms. The prima-
ry ingredients included 12 g of Shanyao (Rhizoma Di-
oseoreae Oppositae), 9 g of Taizishen (Radix Pseudostel-
lariae), 12 g of Fuling (Poria), 9 g of Tusizi (Semen
Cuscutae), and 9 g of Huangqi (Radix Astragali Mon-
golici). If cough became worse, Shegan (Rhizoma Be-
lamcandae) mixture regimen mentioned above was ad-
ministered (ibid). Patients who had a stuffy nose with
sneezing received an additional 9 g of Xinyi (Flos Mag-
noliae Biondii Immaturus) and 9 g of Cang'erzi (Fruc-
tus Xanthii). Patients with night sweats were adminis-
tered 9 g of Mahuanggen (Radix Ephedrae Sinicae)
and 10 g of Fuxiaomai (Fructus Tritici Levis). Patients
took 60-90 mL of this mixture 2 times a day, for 3
months.
In the Western medication group children at the acute
stage of asthma were treated with 4 mg (wight≥20 kg)
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or 2 mg (wight<20 kg) of etinoline (salbutamol sul-
fate), a bronchial relaxant tablet by Shanghai Ethy-
pharm Pharmaceutical Co., Ltd. (Shanghai, China,
batch number 080602) twice a day for 7 days. At the
remission stage, children were given 4-5 mg of the leu-
kotriene receptor antagonist Singulair (Merck Pharma-
ceutical Co., Ltd., Whitehouse Station, NJ, USA,
batch number 100563) once daily for 3 months.
In both groups, children who had accompanying bacte-
rial infections were treated with antibiotics based on
their symptoms at the acute attack stage.
Outcome measures
Venous blood samples were collected from children in
both groups before and 3 months after treatment in or-
der to detect the levels of leukotriene (LTE)-4, interleu-
kin (IL)-4, and interferon (IFN)-γ in peripheral blood,
as well as changes in the gene expression levels of the
leukotriene receptor cysteinyl leukotriene receptor 1
(CysLTR1), IL-4, and IFN-γ in peripheral blood
mononuclear cells (PBMC).
Specimen collection and processing
Venous blood samples (3 mL) were taken aseptically
from asthmatic children and heparin sodium was in-
jected into the blood collection tubes with gentle shak-
ing for anticoagulation. Blood plasma was separated by
centrifugation for 5 min at a speed of 2500 r/min and
frozen for later analysis. PBMC were separated with
the Ficoll method (Huajing Biological Engineering Co.
Ltd, Shenzhen, China).
Determination of mRNA expression levels of IL-4,
IFN-γ, and CysLTR1 in PBMC
After separation, precipitation, and washing of PBMC,
total RNA was extracted using Trizol RNA extraction
reagent (Life Technologies (AB & Invitrogen), Carls-
bad CA, USA). RNA was then reverse transcribed into
cDNA, which was stored at﹣20℃ for later use.
The intercalating dye SYBR Green (Toyobo Co. Ltd.,
Osaka, Japan) was used for detection during quantita-
tive real-time Polymerase Chain Reaction (PCR). A
PCR Master Mix kit was provided by Toyobo Co., Ltd.
(Osaka, Japan). Gene sequences were obtained from
the National Center for Biotechnology Information
(NCBI, Bethesda, MD, USA) gene pool. Primer Pre-
mier 5.0 software (PREMIER Biosoft, Palo Alto, CA,
USA) was adopted to design primers, which were syn-
thesized by Shanghai Shenggong Biological Engineer-
ing Co., Ltd. (Shanghai, China). The primer sequenc-
es and product lengths are shown in Table 1. Fluores-
cence-based quantitative real-time PCR reactions in-
cluded 0.5 μL of forward and reverse primer,
0.25 μL of cDNA, 12.5 μL of SYBR Mix solution,
and sterile water to make up the volume to 25 μL.
Reaction conditions were as follows: pre-denaturation
for 20 min at 95℃ followed by denaturation for 30 s
at 95℃ , annealing for 30 s at 54/55℃ , and exten-
sion for 40 s at 72℃ for 40 cycles. A Mastercycler
ep realplex instrument (Eppendorf AG., Hamburg,
Germany) was used for amplification. The
house-keeping gene β-actin was adopted for correc-
tion of mRNA expression.
Determination of the peripheral blood levels of IL-4,
IFN-γ, and LTE-4
Plasma was obtained by sample centrifugation and anti-
coagulation. The content of INF-γ, IL-4, and LTE-4
was detected with a double antibody sandwich enzyme
linked immunosorbent assay (ELISA) kit, according to
the kit instructions. The kits were supplied by Shang-
hai Xitang Biotechnology Co., Ltd. (Shanghai, China)
Optical density (OD) values were detected with an en-
zyme-labeled meter (Ani Labsystems Ltd. Oy, Vantaa,
Finland) at a wavelength of 450 nm. The diluted con-
centration standards used for INF-γ, IL-4, and LTE-4
were: 1000, 500, 250, 125, 62.5, 31.25, 15.625, and
0 pg/mL; 500, 250, 125, 62.5, 31.25L, 15.625, 7.8,
and 0 pg/mL; and 2000, 1000, 500, 250, 125, 62.5,
31.25, and 0 pg/mL, respectively.
Statistical analysis
SPSS version 16.0 (SPSS Inc., Chicago, IL, USA) sta-
tistical software was used for independent samples
t-test analysis, and data are expressed as mean±standard
deviation ( xˉ ± s). P<0.05 was considered statistically
significant.
Gene
β-actin
IL-4
IFN-γ
CysLT1
Forward and reverse primer sequences
(5′→3′)
CAC CAA CTG GGA CG CAT
ATC TGG GTC ATC TTC TCG C
TGC CTC CAA GAA CAC AAC TG
CTC TGGTTG GCT TCC TTC AC
CCA ACG CAA AGC AAT ACA
CAG GCA GGA CAA CCA TTA
GAC AGC CAT GAG CTT TTT CC
CTT TTT GTG GTT TGG CCA TT
Product length
(bp)
138
219
133
155
Annealing temperature (℃)
55
54
55
55
Table 1 Primer sequences and product lengths of genes detected
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RESULTS
Comparison of the mRNA expression levels of IL-4,
IFN-γ, and CysLTR1
In the Chinese medication group, mRNA expression
levels of IL-4 and CysLTR1 were down-regulated (P<
0.01) and IFN-γ mRNA expression was up-regulated
(P<0.05) after treatment. In the Western medication
group, mRNA expression of IL-4 and CysLTR1 was
also down-regulated (P<0.05) and the mRNA expres-
sion of IFN-γ was up-regulated (P<0.05) after treat-
ment (Table 2). No significant differences were
found between the two groups after treatment (P>
0.05) (Table 3).
Comparison of the peripheral blood levels of INF-γ,
IL-4, and LTE4
In the Chinese medication group, IL-4 blood levels
were significantly decreased and IFN-γ blood levels
were significantly increased after treatment (P<0.05),
and IL-4 levels were significantly reduced (P<0.05)
when compared with the Western medication group.
There was no significant change in LTE-4 blood levels
in the Chinese medication group. In the Western medi-
cation group, IL-4, IFN-γ, and LTE4 levels were not
significantly changed. (Tables 4, 5).
DISCUSSION
Bronchial asthma is an allergic disease due to an im-
Gene
IL-4
IFN-γ
CysLTR1
Chinese medication group (n=27)
Before treatment
2.8±0.7
2.3±0.7
2.5±0.5
After treatment
1.9±0.7
2.8±0.5
1.9±0.4
t value
3.76
﹣2.27
3.57
P value
0.001
0.029
0.001
Western medication group (n=17)
Before treatment
3.1±0.8
2.5±0.5
2.3±0.6
After treatment
2.3±0.8
3.0±0.6
1.8±0.4
t value
2.39
﹣2.16
2.36
P value
0.02
0.04
0.02
Table 2 Comparison of the gene expression levels of IL-4, IFN-γ, and CysLTR1 in the Chinese medication and Western Medication
groups before and after treatment (copy number/ng, xˉ ±s)
Notes: patients in Chinese medication group, at the acute stage of asthma were given Shegan (Rhizoma Belamcandae) mixture, 10 mL, 3
times a day, for 7 days; at the remission stage, were treated with a Huangqi (Radix Astragali Mongolici) Bushen mixture, 60-90 mL, 2 times
a day, for 3 months. In the Western medication group patients at the acute stage of asthma were treated with 4 mg (wight≥20kg) or 2 mg
(wight<20 kg) of etinoline (salbutamol sulfate), twice a day for 7 days; At the remission stage, were given 4-5 mg of the leukotriene recep-
tor antagonist Singulair once daily for 3 months. IL-4: interleukin-4; IFN-γ: interferon-γ; CysLTR1: cysteinyl leukotriene receptor 1.
Gene
IL-4
IFN-γ
CysLTR1
Before treatment
Chinese
medication group
(n=27)
2.8±0.7
2.3±0.7
2.5±0.5
Western
medication group
(n=17)
3.1±0.8
2.5±0.5
2.3±0.6
t
value
﹣1.47
﹣1.41
1.22
P
value
0.15
0.16
0.23
After treatment
Chinese
medication
group (n=27)
1.9±0.7
2.8±0.5
1.9±0.4
Western
medication
group (n=17)
2.3±0.8
3.0±0.6
1.8±0.4
t
value
﹣1.28
﹣1.08
0.89
P
value
0.21
0.30
0.39
Table 3 Comparison of the gene expression levels of IL-4, IFN-γ, and CysLTR1 between the two groups before and after treatment
(copy number/ng, xˉ ±s)
Notes: patients in Chinese medication group, at the acute stage of asthma were given Shegan (Rhizoma Belamcandae) mixture, 10 mL, 3
times a day, for 7 days; at the remission stage, were treated with a Huangqi (Radix Astragali Mongolici) Bushen mixture, 60-90 mL, 2 times
a day, for 3 months. In the Western medication group patients at the acute stage of asthma were treated with 4 mg (wight≥20 kg) or 2 mg
(wight<20 kg) of etinoline (salbutamol sulfate), twice a day for 7 days; At the remission stage, were given 4-5 mg of the leukotriene recep-
tor antagonist Singulair once daily for 3 months. IL-4: interleukin-4; IFN-γ: interferon-γ; CysLTR1: cysteinyl leukotriene receptor 1.
Protein
IL-4
IFN-γ
LTE-4
Chinese medication group (n=27)
Before treatment
55.16±7.88
82.57±24.13
0.56±0.22
After treatment
48.50±9.40
115.22±53.56
0.47±0.25
t value
2.23
﹣2.70
1.15
P value
0.03
0.01
0.26
Western medication group (n=17)
Before treatment
60.04±15.53
88.93±19.16
0.53±0.46
After treatment
58.83±8.33
101.12±35.23
0.37±0.34
t value
0.22
﹣1.15
0.91
P value
0.83
0.26
0.37
Notes: patients in Chinese medication group, at the acute stage of asthma were given Shegan (Rhizoma Belamcandae) mixture, 10 mL, 3
times a day, for 7 days; at the remission stage, were treated with a Huangqi (Radix Astragali Mongolici) Bushen mixture, 60-90 mL, 2 times
a day, for 3 months. In the Western medication group patients at the acute stage of asthma were treated with 4 mg (wight≥20 kg) or 2 mg
(wight<20 kg) of etinoline (salbutamol sulfate), twice a day for 7 days; at the remission stage, were given 4-5 mg of the leukotriene recep-
tor antagonist Singulair once daily for 3 months. IL-4: interleukin-4; IFN-γ: interferon-γ; CysLTR1: cysteinyl leukotriene receptor 1.
Table 4 Comparison of the peripheral blood levels of IL-4, IFN-γ, and LTE-4 in the Chinese medication and Western Medication
groups before and after treatment (ng/mL, xˉ ±s)
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mune system disorder, and persistent asthma or repeat-
ed asthma attacks are related to an imbalance in the ra-
tio of Th1/Th2 immune cells. Increased number and
activation status of Th2 cells causes elevated secretion
of Th2-type cytokines (IL-4 and IL-5), which is a criti-
cal factor in the initiation and maintenance of airway
inflammation. Therefore, it is generally considered that
superiority or excessive differentiation of Th2 cells ex-
ists in the pathogenesis of asthma.6 It has been ob-
served that superiority of Th2 cells is the key mecha-
nism involved in the formation and progress of allergic
asthma. However, the asthma phenotype is not deter-
mined by an increased number of Th2 cells alone, but
also by the Th1/Th2 cell ratio shifting towards Th2.7 A
previous study showed that the ratio of Th1/Th2 cells
was significantly decreased at the acute stage in asth-
matic children. The ratio of Th1/Th2 cells in asthmat-
ic children at the convalescent stage can increase, but is
still lower than that in normal children.8 IFN-γ and
IL-4 are characteristic cytokines of the Th1 and Th2
cell subgroups, respectively, and can be measured to re-
flect the immune response of Th1/Th2 cells in vivo.
Our study was designed to detect the gene expression
of the cytokines associated with the Th1/Th2 ratio
(IL-4 and IFN-γ). It was found that both mRNA ex-
pression and peripheral blood levels of IL-4 were signif-
icantly down-regulated (P<0.01) after treatment with
Chinese medication, while only IL-4 mRNA expres-
sion levels, but not IL-4 blood levels, were changed in
the Western medication group. The mRNA expression
and blood levels of IFN-γ were up-regulated (P<0.05)
in the Chinese medication group, and Chinese medica-
tion also had a more considerable effect on IFN-γ than
Western medication.
In recent years, studies have also shown that the cyste-
inyl leukotrienes are important inflammatory media-
tors in the pathogenesis of asthma.9 Cysteinyl leukotri-
enes are 5-lipoxygenase metabolites of arachidonic ac-
id, that have positive effects via their specific surface re-
ceptors and play a pivotal role in the pathogenesis of
asthma. Both CysLTR1 and CysLTR2 are G-protein
coupled receptors. It has been found that CysLTR1 can
be expressed in eosinophils,as well as airway smooth
muscle cells, airway fibroblasts, and, to a limited ex-
tent, airway epithelial cells. The stimulation of CysL-
TR1 by leukotrienes can evoke contraction and prolif-
eration of smooth muscle cells, mucosal edema, eosino-
phil aggregation, and an increase in mucus secretion,
which lead directly to the development of asthma.10
Studies have suggested that asthma is a disease of multi-
factorial inheritance influenced by a variety of minor
genes including the leukotriene receptor genes. The sex
of the patient has no significant influence on leukotri-
ene receptor gene expression, while it can affect the in-
cidence of asthma.11 The expression of CysLTR1 and
CysLTR2 has been identified in the peripheral blood
leukocytes of asthmatic children, and sex and age had
no significant influence on the expression levels of leu-
kotriene receptor mRNA in this group.12 Leukotriene
receptor gene mRNA encoding is controlled by the ge-
netic information associated with asthma, and is an im-
portant factor in this disease.13 As a result, the control
of leukotriene receptor expression during asthma at-
tacks is critical in the treatment of asthma. In the cur-
rent study, RT-PCR was adopted to detect the gene ex-
pression of CysLTR1 in the PBMC of the two groups
before and after treatment. The results suggest that
CysLTR1 mRNA expression was significantly
down-regulated in the Chinese medication group (P<
0.01) and this effect was similar with that in patients
treated with a leukotriene receptor antagonist.
Professor Yumin Shi treats pediatric asthma based on
the different stages and symptoms of this disease. At
the acute attack stage, the main therapeutic principle is
clearing of the lungs by eliminating phlegm and facili-
tating the flow of gastric Qi to relieve asthma. At the re-
mission stage, nourishing Qi to invigorate the spleen
and kidney is considered as the principle method,
which has a good clinical effect. The present study
showed that stage-treatment with TCM for pediatric
asthma may be associated with inhibition of leukotri-
ene receptor gene expression, which can result in a de-
crease of the inflammatory effects of leukotrienes on
the respiratory tract and inhibition of the onset of asth-
ma. At the same time, the results demonstrated that
TCM formulas could improve the expression and
Protein
IL-4
IFN-γ
LTE-4
Before treatment
Chinese
medication
group (n=27)
55.16±7.88
82.57±24.13
0.56±0.22
Western
medication group
(n=17)
60.04±15.53
88.93±19.16
0.53±0.46
t
value
-1.38
-0.92
0.91
P
value
0.25
0.36
0.37
After treatment
Chinese
medication group
(n=27)
48.50±9.40
115.22±53.56
0.47±0.25
Western
medication
group (n=17)
58.83±8.33
101.1±35.2
0.37±0.34
t
value
-2.56
0.37
0.80
P
value
0.02
0.72
0.43
Table 5 Comparison of the peripheral blood levels of IL-4, IFN-γ, and LTE-4 between the two groups before and after treatment
(ng/mL, xˉ ±s)
Notes: patients in Chinese medication group, at the acute stage of asthma were given Shegan (Rhizoma Belamcandae) mixture, 10 mL, 3
times a day, for 7 days; at the remission stage, were treated with a Huangqi (Radix Astragali Mongolici) Bushen mixture, 60-90 mL, 2 times
a day, for 3 months. In the Western medication group patients at the acute stage of asthma were treated with 4 mg (wight≥20 kg) or 2 mg
(wight<20 kg) of etinoline (salbutamol sulfate), twice a day for 7 days; at the remission stage, were given 4-5 mg of the leukotriene recep-
tor antagonist Singulair once daily for 3 months. IL-4: interleukin-4; IFN-γ: interferon (IFN)-γ; CysLTR1: cysteinyl leukotriene receptor 1.
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blood levels of IFN-γ, i.e., TCM may cause increased
Th1 cell function, which can inhibit viral infection-re-
lated asthma. After treatment with TCM, blood levels
of IL-4 were also reduced, indicating that TCM may re-
duce Th2 cell function. It would inhibit the initiation
and maintenance of airway inflammation, meaning
that TCM can regulate the imbalanced ratio of Th1/
Th2 cells in asthma. In summary, a series of empirical
prescriptions for asthma attack can play a regulatory
role in the pathogenesis of this disease.
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